Quarterly report [Sections 13 or 15(d)]

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.25.1
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Apr. 30, 2025
Apr. 30, 2024
Apr. 30, 2025
Apr. 30, 2024
Oct. 31, 2024
Segment Reporting Information [Line Items]          
Net loss $ (2,813) $ (3,180) $ (6,026) $ (6,470)  
Total operating costs and expenses 3,003 3,467 6,389 7,076  
Less non-cash stock-based compensation (988) (1,260) (2,043) (2,520)  
Operating costs and expenses excluding non-cash stock-based compensation 2,015 2,207 4,346 4,556  
Total assets 16,977   16,977   $ 21,591
Cancer Vaccines [Member]          
Segment Reporting Information [Line Items]          
Net loss (1,879) (1,713) (3,897) (3,469)  
Operating costs and expenses excluding non-cash stock-based compensation 1,364 1,160 2,831 2,373  
Total assets 11,446   11,446   12,917
CAR-T Therapeutics [Member]          
Segment Reporting Information [Line Items]          
Net loss (925) (1,444) (2,101) (2,970)  
Operating costs and expenses excluding non-cash stock-based compensation 643 1,026 1,491 2,154  
Total assets 5,433   5,433   8,535
Other [Member]          
Segment Reporting Information [Line Items]          
Net loss (9) (23) (28) (31)  
Operating costs and expenses excluding non-cash stock-based compensation 8 $ 21 24 $ 29  
Total assets $ 98   $ 98   $ 139